Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists

Journal of Medicinal Chemistry

Volumn 44, Issue 11, 2001, Pages 1675-1689

  Blaney, F E ^a   Raveglia, L F ^b   Artico, M ^b   Cavagnera, S ^b   Dartois, C ^c   Farina, C ^b   Grugni, M ^b   Gagliardi, S ^b   Luttmann, M A ^a   Martinelli, M ^b   Nadler, G M M G ^c   Parini, C ^b   Petrillo, P ^b   Sarau, H M ^a   Scheideler, M A ^b   Hay, D W P ^a   Giardina, G A M ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b SmithKline Beecham SpA   (Italy)

^c SmithKline Beecham Laboratoires Pharmaceutiques   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOCKING PROTEIN; MU OPIATE RECEPTOR; N (1 CYCLOHEXYLETHYL) 3 [(4 MORPHOLIN 4 YL)PIPERIDIN 1 YL]METHYL 2 PHENYLQUINOLINE 4 CARBOXAMIDE; N (1,2,2 TRIMETHYLPROPYL) 3 [(4 PIPERIDIN 1 YL)PIPERIDIN 1 YL]METHYL 2 PHENYLQUINOLINE 4 CARBOXAMIDE; NEUROKININ 2 RECEPTOR; NEUROKININ 3 RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; CHO CELLS; CLONING, MOLECULAR; CRICETINAE; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MORPHOLINES; PIPERIDINES; QUINOLINES; RADIOLIGAND ASSAY; RECEPTORS, NEUROKININ-2; RECEPTORS, NEUROKININ-3; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035942516     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000501v     Document Type: Article

References (68)

1. Receptors and antagonists for substance P and related peptides
2. Lead generation and lead optimization processes in the discovery of selective nonpeptide neurokinin receptor antagonists
3. Recent advances in neurokinin receptor antagonists
4. Neurokinin antagonists as potential therapies for inflammation and rheumatoid arthritis
5. Neurokinin receptor antagonists
6. Neurokinin receptor antagonists
7. Recent advances in neurokinin-3 receptor antagonists
8. Electrophysiological effects of tachykinins and capsaicin on guinea-pig bronchial parasympathetic neurones
9. Tachykinins in the autonomic nervous system
10. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412)
11. Nonpeptide tachykinin receptor antagonists. I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective NK-3 receptor antagonist
12. 2-Phenyl-4-quinolinecarboxamides: A novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptor
13. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework
14. 7] neurokinin B to the neurokinin-3 receptor
15. 9]-neurokinin-A binding to NK-2 receptors on hamster urinary bladder membranes
16. Binding characteristics and affinity labeling of protein constituents of the human IM-9 lymphoblast receptor for substance P
17. The antitussive activity of delta opioid receptor stimulation in guinea pigs
18. Reconstitution of solubilized deltaopiate receptor binding sites in lipidic vesicles
19. 50) of an enzymatic reaction
20. Biarylcarbamoylindolines are novel and selective 5-HT2C receptor inverse agonists: Identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl] carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent
21. The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]carbonyl]-2,3,6,7-te trahydrospiro[furo[2,3-flindole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo
22. G-protein coupled receptors: Models, mutagenesis, and drug design
23. Projection structure of rhodopsin
24. Arrangement of rhodopsin transmembrane α-helixes
25. An alpha-carbon template for the transmembrane helixes in the rhodopsin family of G-protein-coupled receptors
26. A simple method for displaying the hydropathic character of a protein
27. Solvent induced distortions and the curvature of α-helices
28. Helanal - A novel algorithm for the construction of transmembrane helical bundles
29. The prediction and orientation of α-helixes from sequence alignments: The combined use of environment-dependent substitution tables. Fourier transform methods and helix capping rules
30. A single point mutation (Phe340→Leu340) of a conserved phenylalanine abolishes 4-[125I]-iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors
31. Identification of residues required for ligand binding to the β-adrenergic receptor
32. Site-directed mutagenesis of the human dopamine D2 receptor
33. Identification of two serine residues involved in agonist activation of the β-adrenergic receptor
34. Functional role of proline and tryptophan residues highly conserved among G protein-coupled receptors studied by mutational analysis of the m3 muscarinic receptor
35. A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice
36. Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice
37. Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice
38. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice
39. Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: Contributions of the second membrane-spanning segment
40. A common step for signal transduction in G protein-coupled receptors
41. Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor
42. Interactions between conserved residues in transmembrane helixes 1, 2, and 7 of the thyrotropin-releasing hormone receptor
43. Computational tools and results in the construction of G protein-coupled receptor models
44. Backbone-dependent rotamer library for proteins. Application to side-chain prediction
45. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations
46. Site-directed mutagenesis of a single residue changes the binding properties of the serotonin 5-HT2 receptor from a human to a rat pharmacology
47. Conversion of antagonist-binding site to metal-ion site in the tachykinin NK-1 receptor
48. SR 142801, the first potent non-peptide antagonist of the tachykinin NK-3 receptor
49. Crystal structure of rhodopsin: AG protein-coupled receptor
50. β-turns and their distortions: A proposed new nomenclature
51. Enhanced sampling in molecular dynamics: Use of the time-dependent Hartree approximation for a simulation of carbon monoxide diffusion through myoglobin
52. Modeling side chains in peptides and proteins: Application of the locally enhanced sampling and the simulated annealing methods to find minimum energy conformations
53. Reductions with ruthenium. II. Its use in the hydrogenation of pyridines
54. 5-(1-Piperazinyl)-1H-1,2,3,4-triazol-3-amines as antihypertensive agents
55. Resolution of amines with isopropylidene glycerol hydrogen phthlate